Elpiscience (Suzhou) Biopharma, Ltd.
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | OX40 (agonist)Monoclonal antibody | Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
February 2027 (1)
Est. primary completion 2027-02-28 · NCT06623136 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
OrdastobartPhase 2/3Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Est. primary completion 2029-12 · NCT06295731 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
OrdastobartPhase 1/2Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma …
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.